Clovis Oncology Inc. (NASDAQ:CLVS) shares fell 4.4% during mid-day trading on Wednesday . The stock traded as low as $13.92 and last traded at $14.07, with a volume of 250,284 shares. The stock had previously closed at $14.71.

Several analysts recently weighed in on the stock. Credit Suisse Group AG assumed coverage on shares of Clovis Oncology in a research note on Monday, April 18th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. cut shares of Clovis Oncology from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $42.00 to $15.00 in a research note on Wednesday, April 13th. Zacks Investment Research cut shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research report on Tuesday, April 12th. Vetr cut shares of Clovis Oncology from a “strong-buy” rating to a “buy” rating and set a $17.66 price target on the stock. in a research report on Wednesday, May 25th. Finally, Mizuho reaffirmed a “hold” rating on shares of Clovis Oncology in a research report on Wednesday, April 13th. Seven investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $29.25.

The firm has a 50 day moving average price of $14.65 and a 200-day moving average price of $18.08. The firm’s market cap is $544.68 million.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.39) by $0.22. During the same quarter in the prior year, the business posted ($1.86) earnings per share. The company’s revenue for the quarter was up NaN% compared to the same quarter last year. Equities research analysts expect that Clovis Oncology Inc. will post ($8.00) earnings per share for the current fiscal year.

Other large investors have recently made changes to their positions in the company. Rhumbline Advisers raised its stake in shares of Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock worth $1,058,000 after buying an additional 1,880 shares during the period. ProShare Advisors LLC raised its stake in shares of Clovis Oncology by 9.5% in the fourth quarter. ProShare Advisors LLC now owns 36,129 shares of the biopharmaceutical company’s stock worth $1,265,000 after buying an additional 3,125 shares during the last quarter. California State Teachers Retirement System raised its stake in shares of Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock worth $1,806,000 after buying an additional 889 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in shares of Clovis Oncology during the fourth quarter worth $3,170,000.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.